UT-San Antonio, Health Science Center, Merck Pen Exclusive Deal to Develop Chlamydia Vaccine | GenomeWeb

The University of Texas at San Antonio and the University of Texas Health Science Center at San Antonio said this week that they have entered into an exclusive license and sponsored-research agreement with Merck to develop a vaccine for chlamydia.

According to the schools, the deal is noteworthy because it is the first revenue-producing license for any technology developed at UTSA.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.